Each cancer journey is unique and deeply personal, making it complex to comprehend fully. We understand that every cancer patient is also a parent, partner, friend, or child who cherishes moments of love and connection. With this awareness, our scientific research and cancer studies are driven by the desire to witness more smiles, warm embraces, and meaningful touches – we know their significance. A cancer diagnosis should not rob them of these essential moments. This belief fuels our relentless work to cater to patients' needs in the best possible manner.
TOGETHER FOR PATIENTS. TOGETHER FOR THOSE WHO STAND BESIDE THEM.
Our Disease Areas
With passion for true innovation we seek to transform standards in cancer patient care. All our scientific and research efforts seek to address areas of unmet medical need. We want to contribute to the enrichment of quality of life around the world by creating innovative pharmaceuticals that address the diverse medical needs of patients in the communities we serve.
World-Class Science Organization
We are committed to becoming a world-class science organization. Our team’s exceptional scientific attitude results in outstanding medicinal chemistry, antibody engineering and discovery biology.
Dynamic and Sustainable R&D Engine
The oncology portfolio of Daiichi Sankyo is powered by our research engine: Biologics, medicinal chemistry, modality, and other research laboratories in Japan.
“3 and Alpha” R&D Strategy
Anchored by our DXd antibody drug conjugate (ADC) technology, our obligation is to harness the power of true innovation to discover and develop innovative first-in-class and best-in-class treatments that transform the standard of care for patients with cancer.
Enhanced Capabilities Through Collaboration
To complement and expand our premier cadre of internal scientists, we are collaborating with leading academic and business partners to leverage cutting-edge science in new treatment modalities, disease biology, diagnostics and pipeline prioritization.
References
1 As of March 31, 2022
https://www.daiichisankyo.com/files/investors/library/materials/2021/20210405_5th_MTP_E.pdf
Source: Financial Highlights – Daiichi Sankyo https://www.daiichisankyo.com/investors/financial_highlights
2 https://www.daiichisankyo.com/files/investors/library/quarterly_result/2020/pdf/FY2020_Q4_
Financial_Results_Presentation_EE.pdf
For legal reasons detailed information about prescription medicine may only be given to healthcare professionals. The agents discussed on the website are investigational and have not been approved by the EMA or any other regulatory agency worldwide as a treatment for any indication. Safety and efficacy have not been established. There is no guarantee that these compounds will become commercially available.
